Day: October 7, 2024

Real-time Data Helps Research on when Older People Fall

Photo by Kampus Production on Pexels

When older people lose their balance, they often struggle to recall the circumstances, making studying this phenomenon challenging. Now, a Virginia Tech study using wrist-worn voice recorders concludes that voice recorders are effective at capturing the circumstances and context in which they lost their balance and potentially fell, without relying on recall later. The findings were recently published in the Journal of American Geriatrics Society.

The study, led by Michael Madigan in the College of Engineering, builds on years of his own foundational work and prior research conducted by the University of Michigan Medical School.  “In the past, researchers would ask participants to recall what they were doing when they lost their balance, but memory can be unreliable,” said Madigan. “With this new method, participants record their experiences immediately after an incident, providing much more accurate and detailed information.” 

Real-world insight

In this study, 30 participants, who averaged around 72 years of age, wore voice recorders on their wrists over the course of three weeks, and in the event of balance loss, turned them on to record answers to these key questions: 

  • When and where did the balance loss occur? 
  • What were they doing at the time? 
  • How did they attempt to regain their balance – did they grab a railing, take steps, or sit down? 
  • Why do they think they lost their balance? 
  • Did they fall? 

This immediate, self-reported data was analysed by Madigan and his team. Instead of waiting to meet with researchers after losing their balance, participants could reflect on what happened in the moment. 

“We’re trying to better understand the circumstances in which people lose their balance,” Madigan said. “This process doesn’t require people to think back weeks or months to an incident, especially when memory can be unreliable.” 

Participant experience

Maria Moll, a retired epidemiologist and study participant, found the research particularly meaningful, especially as someone in her 70s who remains physically active. After a friend experienced a fall, Moll became more interested in contributing to balance-loss prevention research. 

“I’ve always been interested in physical fitness and balance, especially as I age,” said Moll. “This study made me more mindful of my movements, particularly during more challenging activities like hiking.” 

The future of real-world data collection

Looking ahead, the team plans to expand the study to larger groups and combine the data with other lab-based measurements. By doing so, they hope to identify individuals who are most at risk of balance loss and develop strategies to proactively address those risks. 

“We want to give clinicians the tools to intervene before a fall occurs,” said Madigan. “This method can provide more reliable, detailed information that helps us understand not just how people lose their balance, but why.” 

Source: Virginia Tech

From Stress to Strength: The Impact of Mental Health Support in the Workplace

Photo by Usman Yousaf on Unsplash

As the world continues to face unprecedented challenges, including geopolitical tensions, extreme weather events, disease outbreaks, and economic uncertainty, the mental health of employees has become a pressing concern. This year’s World Mental Health Day theme, “Mental Health at Work”, is a crucial reminder for organisations to take action to safeguard their workforce’s mental health and wellbeing. In alignment with this theme, International SOS, the world’s leading health and security risk services company, encourages organisations worldwide to recognise the critical importance of mental wellbeing and resilience within their workforce.

Heightened anxiety

The increasing frequency and intensity of global crises, coupled with elevated job demands, are contributing to heightened levels of stress and anxiety, further exacerbating mental health concerns among the global workforce. According to the World Health Organization (WHO), an estimated 15% of working-age adults are experiencing a mental disorder at any single point in time.

Additionally, International SOS assistance data(2022 – 2024) reveals that over the past two years, the top five mental health-related assistance requests the organisation received are:

  1. Anxiety
  2. Depression
  3. Panic disorder
  4. Attention Deficit Hyperactivity Disorder (ADHD)
  5. Acute stress 

Burnout has also become a prominent issue among employees, with one in four employees worldwide reporting symptoms of burnout. The International SOS Risk Outlook 2024 report highlights employee burnout as a major threat impacting organisations.

Economic impact

Moreover, the economic impact of mental health issues cannot be ignored. The WHO estimates that globally, approximately 12 billion working days are lost annually to depression and anxiety, resulting in US$ 1 trillion in lost productivity per year. These figures highlight the importance for employers to create a workplace that promotes mental wellbeing and underscores the immense cost of neglecting employee mental health and wellbeing at work. Organisations play a pivotal role in shaping the mental health landscape by implementing policies and practices that promote wellbeing.

Dr Chris van Straten, Global Health Advisor Clinical Governance at International SOS said, “World Mental Health Day is a timely reminder for organisations to acknowledge and address the profound importance of mental wellbeing within their workforce. The workplace environment can have a significant impact on employee mental health, both positive and negative, by either fostering wellbeing or contributing to stress and anxiety. Just as we invest in employee physical safety, it is important to also understand that mental health is integral to overall health. It is therefore imperative to prioritise mental resilience.”

“Organisations can empower their employees to navigate challenges, thrive and contribute to a more positive and productive workplace by creating a supportive work environment that fosters open communication, empathy and understanding. Providing access to mental health professionals, counselling services, and employee assistance programmes is essential to ensure employees are equipped to navigate the complexities of today’s global landscape.”

To support the mental health and wellbeing of their workforce, International SOS provides advice for organisations:

  1. Cultivate a supportive work culture with strong leadership commitment: Create a workplace culture and environment that prioritises and promotes open communication on mental health. Ensure mental wellbeing initiatives are seamlessly integrated into relevant policies and practices to provide robust support.
  2. Provide accessible resources: Ensure employees have a toolkit of mental health resources at their fingertips, from counselling to self-guidance materials.
  3. Promote work-life balance: Offer flexible work arrangements and remote work options to help employees manage their personal and professional lives effectively. Encourage regular breaks and empower employees to prioritise their wellbeing.
  4. Training and education: Implement comprehensive mental health awareness campaigns to reduce stigma. Roll out mental health training, enabling everyone to spot, understand and assist with mental health challenges.
  5. Monitor and assess: Seek feedback and continuously monitor the mental health of employees through surveys and assessments, and adapt programmes as needed.
  6. Invest in emotional wellbeing: provide access to mindfulness sessions and stress management training—partner with certified mental health professionals to offer confidential counselling and support services.
  7. Employee Assistance Programmes (EAPs): Provide EAPs that offer confidential counselling and support services to employees. Promoting the availability and benefits of EAPs can encourage employees to seek help without fear of stigma, fostering a culture of openness and support.

South African and Australian Health Product Regulators to Share Regulatory Information and Expertise

Photo by Kindel Media

The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators.

The MoU builds on the existing relationship between the health products regulators to improve capabilities in the assessment of medical products and therapeutic goods and their monitoring for continued efficacy, safety and quality once they are registered.

Areas of cooperation

SAHPRA and TGA will engage in data sharing aimed at improving the regulatory functions executed by both regulators. This will particularly focus on the assessment and approval of medical products and therapeutic goods, their monitoring for continued efficacy, and the surveillance for safety and adverse reaction (event) concerns.

According to SAHPRA’s Chief Executive Officer, Dr Boitumelo Semete-Makokotlela, the agreement with the TGA expands the geographical reach for both regulators’ pharmacovigilance programmes and augments their internal expertise.

“This partnership enables us to rely on each other’s strengths and regulatory outputs in the evaluation of health products both before they are registered and once they are approved for public use. This would improve therapeutic outcomes for the populations we exist for and increase the robustness of our post-registration surveillance for efficacy, safety and quality,” says Dr Semete-Makokotlela.

Deputy Secretary at the Australian Government Department of Health and Aged Care and head of the TGA, Professor Anthony Lawler, said: “TGA is very pleased to have strengthened our collaborative relationship with SAHPRA with the signing of this international agreement. We look forward to working alongside our regulatory counterparts in South Africa to share important regulatory information to ensure the continued safety, quality and efficacy of therapeutic products approved for market.”

Source: SAHPRA

What Happens in the Brain When a Person with Schizophrenia ‘Hears Voices’?

Source: Pixabay

Auditory hallucinations are likely the result of abnormalities in two brain processes: a “broken” corollary discharge that fails to suppress self-generated sounds, and a “noisy” efference copy that makes the brain hear these sounds more intensely than it should. That is the conclusion of a new study published October 3rd in the open-access journal PLOS Biology by Xing Tian, of New York University Shanghai, China, and colleagues.

Patients with certain mental disorders, including schizophrenia, often hear voices in the absence of sound.

Patients may fail to distinguish between their own thoughts and external voices, resulting in a reduced ability to recognise thoughts as self-generated.

In the new study, researchers carried out electroencephalogram (EEG) experiments measuring the brain waves of twenty patients diagnosed with schizophrenia with auditory hallucinations and twenty patients diagnosed with schizophrenia who had never experienced such hallucinations.

In general, when people are preparing to speak, their brains send a signal known as “corollary discharge” that suppresses the sound of their own voice.

However, the new study showed that when patients with auditory hallucinations were preparing to speak a syllable, their brains not only failed to suppress these internal sounds, but had an enhanced “efference copy” response to internal sounds other than the planned syllable.

The authors conclude that impairments in these two processes likely contribute to auditory hallucinations and that targeting them in the future could lead to new treatments for such hallucinations.

The authors add, “People who suffer from auditory hallucinations can ‘hear’ sounds without external stimuli. A new study suggests that impaired functional connections between motor and auditory systems in the brain mediate the loss of ability to distinguish fancy from reality.”

Provided by PLOS

New Approach to MS ‘Teaches’ Immune Cells not to Attack

Myelin sheath damage. Credit: Scientific Animations CC4.0

Researchers from have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results, published in the Journal of Clinical Investigation, builds on two harmonised Phase I clinical trials, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patient.

Multiple Sclerosis (MS) is a long-term disease where the immune system mistakenly attacks the protective myelin sheath around nerve cells. This leads to nerve damage and worsening disability. Current treatments, like immunosuppressants, help reduce these harmful attacks but also weaken the overall immune system, leaving patients vulnerable to infections and cancer. Scientists are now exploring a more targeted therapy using special immune cells, called tolerogenic dendritic cells (tolDCs), from the same patients.

TolDCs can restore immune balance without affecting the body’s natural defences. However, since a hallmark of MS is precisely the dysfunction of the immune system, the effectiveness of these cells for auto transplantation might be compromised. Therefore, it is essential to better understand how the disease affects the starting material for this cellular therapy before it can be applied.

In this study, researchers from Barcelona’s Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute, examined CD14+ monocytes, mature dendritic cells (mDCs), and Vitamin D3-treated tolerogenic dendritic cells (VitD3-tolDCs) from MS patients who had not yet received treatment, as well as from healthy individuals. The clinical trials (NCT02618902 and NCT02903537) are designed to assess the effectiveness of VitD3-tolDCs, which are loaded with myelin antigens to help “teach” the immune system to stop attacking the nervous system. This approach is groundbreaking as it uses a patient’s own immune cells, modified to induce immune tolerance, in an effort to treat the autoimmune nature of MS.

The study, led by Dr Eva Martinez-Cáceres and Dr Esteban Ballestar, with Federico Fondelli as first author, found that the immune cells from MS patients (monocytes, precursors of tolDCs) have a persistent “pro-inflammatory” signature, even after being transformed into VitD3-tolDCs, the actual therapeutic cell type. This signature makes these cells less effective compared to those derived from healthy individuals, missing part of its potential benefits.

Using state-of-the-art research methodologies, the researchers identified a pathway, known as the Aryl Hydrocarbon Receptor (AhR), that is linked to this altered immune response. By using an AhR-modulating drug, the team was able to restore the normal function of VitD3-tolDCs from MS patients, in vitro. Interestingly, Dimethyl Fumarate, an already approved MS drug, was found to mimic the effect of AhR modulation and restore the cells’ full efficacy, with a safer toxic profile.

Finally, studies in MS animal models showed that a combination of VitD3-tolDCs and Dimethyl Fumarate led to better results than using either treatment on its own. This combination therapy significantly reduced symptoms in mice, suggesting enhanced potential for treating human patients.

These results could lead to a new, more potent treatment option for multiple sclerosis, offering hope to the millions of patients worldwide who suffer from this debilitating disease. This study represents a significant step forward in the use of personalised cell therapies for autoimmune diseases, potentially revolutionising how multiple sclerosis is treated.

The team is now preparing to move into Phase II trials to further explore these findings.

Source: Josep Carreras Leukaemia Research Institute